Indications
Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.
Composition
- Active substance
- buprenorphine, naloxone
- International name (INN)
- buprenorphine;naloxone
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Suboxone
- Active substance
- buprenorphine, naloxone
- ATC code
- N07BC51
- Group
- Nervous system
- Therapeutic area
- Opioid-Related Disorders